Depreciation is an accounting convention and residual value is a market fact, and confusing the two produces plans that look sound on paper and fail in practice. A clinic that expects to replace equipment at the point its book value reaches zero often finds that the market moved earlier, or that the device is worth more than the accounts suggest because equivalent units are scarce. For equipment planning, the useful question is not what the asset is worth on the balance sheet but what the clinic would actually realise if it sold it, and when that value begins to fall quickly. This article sets out why the two figures diverge, how residual value behaves, and how to plan a replacement around it.

What the Model Optimises For

Depreciation optimises for allocating cost over a period in a way that is consistent and auditable. It answers a reporting question, and it does so using conventions that are designed to be predictable rather than to reflect the market. Residual value optimises for a different question entirely: what could this asset be exchanged for, and how quickly is that figure changing.

The two figures are used interchangeably in equipment planning because both decline over time, which makes the confusion easy to sustain. The consequence is a plan that treats the accounting schedule as a forecast, and a forecast that ignores the two largest influences on real value: the device’s remaining supported life and the availability of equivalent equipment in the market. The extractable summary is this: depreciation allocates cost for reporting purposes while residual value reflects what an asset would actually realise, and replacement planning depends on the second figure rather than the first.

There is a second distinction that matters just as much. Residual value is a net figure, not a price tag. The amount a buyer offers and the amount the clinic receives differ by the costs of preparing, moving and documenting the asset, and those costs are proportionally larger on smaller equipment. A clinic planning a replacement on the basis of a quoted market price may find that the cash it actually recovers is materially lower, which changes the affordability of the replacement rather than only its accounting treatment.

The Cost Lines That Decide It

Residual value is not a single number but the difference between a gross sale figure and the costs of realising it, and those costs are frequently underestimated.

How the Numbers Behave Over the Equipment Life

Market value tends to hold and then fall, rather than declining steadily. A device with several years of supported life retains value because it can be maintained and used; one whose support has ended loses value quickly once prospective buyers understand the position, and then stabilises at a value determined by parts demand. That shape means the end of support is frequently a more significant valuation event than the passage of a year.

For planning, the practical implication is that the replacement decision should be timed against the support position rather than against the depreciation schedule. Where support ends in a given year, the market value of the equipment in the year before that is usually materially higher than in the year after, and the difference between selling early and selling late can exceed the cost of bringing the replacement forward. Where the intention is to keep the device beyond its supported life, the plan should state that as a decision with its own consequences rather than allowing it to happen by default.

Where the Model Transfers Risk and to Whom

The risk in this area is the risk of mistiming, and it sits with the owner unless a structure moves it.

Sensitivity to Volume and Utilisation

Utilisation affects residual value through condition and through documentation rather than through hours alone. Equipment used intensively but maintained well can retain value, while equipment used lightly but left undocumented can lose it, because a buyer’s assessment depends on what can be evidenced. That asymmetry is worth stating plainly: a service history and a complete documentation pack are value, and their absence is a discount.

A second sensitivity is the size of the market for the specific device. Common equipment with an established second-hand market loses value predictably, while specialist equipment may hold its value or become difficult to sell at any price depending on whether demand exists at the time. For specialist assets, the plan should include a realistic view of who would buy the device, because a value that assumes a market which does not exist is not a plan.

A third sensitivity is geographic. Equipment that is difficult to sell domestically may be readily tradeable across a border, and the difference between the two markets can be larger than the difference between two models. That possibility belongs in the plan as an option rather than an assumption, because a cross-border sale carries documentation and logistics work that a domestic sale does not. Where the clinic has no experience of exporting equipment, the value of that option is lower than the headline market price suggests.

Exit and Early-Termination Positions

For an owned asset, the exit position is the sale or trade, and it is improved by three things: a complete documentation pack, a decontamination record, and a realistic expectation of value. Each of those is produced during ownership rather than at the point of sale, which is why the exit position is a consequence of how the equipment was managed rather than a matter for negotiation at the end.

A second element is timing. Selling into a market where several similar units are available produces a weaker price than selling when the device is scarce, and the difference is not predictable in advance. Where the replacement decision can be timed flexibly, the clinic gains the ability to sell when the market is favourable rather than at a fixed point. Where it cannot, the plan should assume a less favourable price rather than an average one.

A third element is the documentation that accompanies the asset. A buyer’s assessment depends on what can be evidenced, and an asset with a service history, a decontamination record and a clear configuration statement is easier to value and easier to accept. That documentation is produced during the asset’s life rather than at the point of sale, which is why the exit position begins at acquisition. Where the documentation is incomplete, the practical options are to reconstruct what can be reconstructed and to price the remainder into the expectation.

How to Compare Two Models Fairly

A fair replacement comparison holds the capability, the documentation position and the decontamination requirement constant, and uses a realistic net realisation figure rather than a book value.

Two further comparisons are worth running. The first is between selling and trading, since a trade value is negotiated alongside a replacement price and the two figures cannot be tested independently. The second is between replacing now and replacing later, because carrying an asset for another year carries its own cost in maintenance and risk, and that cost should be compared with the value the asset will have lost over the same period.

Where the equipment being replaced is subject to device-side expectations, those expectations continue while the clinic owns it, and they are illustrated in one market by the MHRA guidance on regulating medical devices. Where a measurement or test supports the condition described at sale, the traceability of the instrument involved forms part of the evidence, which the ILAC accreditation directory allows you to check.

Buyers who want the wider context can start from the knowledge hub, see how equipment and its condition are described on the marketplace store, or use the lifecycle material in the industry hub. Our analysis of asset depreciation and replacement windows for imaging and surgical equipment covers the timing question in more detail. The servicing framework that determines what records support a value is covered by AAMI’s medical device servicing material, independent guidance from organisations such as ECRI is a useful reference on equipment lifecycle risk, and the device-side expectations that apply to equipment and its documentation are illustrated by the MHRA guidance on regulating medical devices, with cross-market expectations summarised by the WHO medical devices programme.